- Main
Low Prevalence of Interferon α Autoantibodies in People Experiencing Symptoms of Post–Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID
- Peluso, Michael J;
- Mitchell, Anthea;
- Wang, Chung Yu;
- Takahashi, Saki;
- Hoh, Rebecca;
- Tai, Viva;
- Durstenfeld, Matthew S;
- Hsue, Priscilla Y;
- Kelly, J Daniel;
- Martin, Jeffrey N;
- Wilson, Michael R;
- Greenhouse, Bryan;
- Deeks, Steven G;
- DeRisi, Joseph L;
- Henrich, Timothy J
Published Web Location
https://doi.org/10.1093/infdis/jiac372Abstract
Interferon (IFN)-specific autoantibodies have been implicated in severe coronavirus disease 2019 (COVID-19) and have been proposed as a potential driver of the persistent symptoms characterizing "long COVID," a type of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report that only 2 of 215 participants with convalescent SARS-CoV-2 infection tested over 394 time points, including 121 people experiencing long COVID symptoms, had detectable IFN-α2 antibodies. Both had been hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to long COVID symptoms in the postacute phase of the infection.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.